Glimidip, Glimepiride 2 mg + Voglibose 0.2 mg + Metformin 500 mg (SR), Glimepiride, Voglibose, Metformin, Glimidip-MV2 daksh, daksh diabetic and cardiac, daksh pharma panchkula, daksh diabetic and cardiac panchkula, pcd franchise, pcd franchise company in panchkula, daksh group, pharma companies, pharma products, franchise, speciality product
daksh diabetic and cardiac, dalsh cardiac, daksh pharmaceuticals , daksh pharma panchkula, cardiac pcd franchise, daksh panchkula, cardiac medicine, heart medicine, glimidac range, diabetix products, glimidac-1, glimidac 2
daksh diabetic and cardiac, dalsh cardiac, daksh pharmaceuticals , daksh pharma panchkula, cardiac pcd franchise, daksh panchkula, cardiac medicine, heart medicine, glimidac range, diabetix products, glimidac-1, glimidac 2
Glimidip, Glimepiride 2 mg + Voglibose 0.2 mg + Metformin 500 mg (SR), Glimepiride, Voglibose, Metformin, Glimidip-MV2 daksh, daksh diabetic and cardiac, daksh pharma panchkula, daksh diabetic and cardiac panchkula, pcd franchise, pcd franchise company in panchkula, daksh group, pharma companies, pharma products, franchise, speciality product
daksh diabetic and cardiac, dalsh cardiac, daksh pharmaceuticals , daksh pharma panchkula, cardiac pcd franchise, daksh panchkula, cardiac medicine, heart medicine, glimidac range, diabetix products, glimidac-1, glimidac 2
daksh diabetic and cardiac, dalsh cardiac, daksh pharmaceuticals , daksh pharma panchkula, cardiac pcd franchise, daksh panchkula, cardiac medicine, heart medicine, glimidac range, diabetix products, glimidac-1, glimidac 2

GLIMIDAC MV

TAB GLIMIDAC MV 1 (Glimepiride 1 mg + Voglibose 0.2 mg
+ Metformin 500 mg (SR))		 BLISTER 10 X 15
TAB GLIMIDAC MV 2 (Glimepiride 2 mg + Voglibose 0.2 mg
+ Metformin 500 mg (SR))		 BLISTER 10 X 15
TAB GLIMIDAC MV 3.2 (Glimepiride 3 mg + Voglibose 0.2 mg
+ Metformin 500 mg (SR))		 BLISTER 10 X 15
TAB GLIMIDAC  MV 1 FORTE (Glimepiride 1 mg + Voglibose 0.3mg
+ Metformin 500 mg (SR)		 BLISTER 10 X 15
TAB GLIMIDAC MV 2 FORTE (Glimepiride 2mg + Voglibose 0.3mg
+ Metformin 500 mg (SR))		 BLISTER 10 X 15
Category: Tag:
Send Enquiry

Introduction:

GLIMIDAC MV is an advanced triple-drug oral antidiabetic combination of Glimepiride, Metformin SR, and Voglibose. It is designed for patients with Type 2 Diabetes Mellitus (T2DM) who experience significant postprandial hyperglycemia despite dual therapy. This formulation offers complementary mechanisms of action to target insulin resistance, inadequate insulin secretion, and rapid post-meal glucose spikes.

Each variant is available in blister packs (10 x 15 tablets) to ensure patient convenience and adherence.

Product Variants & Composition:

GLIMIDAC MV 1

  • Composition: Glimepiride 1 mg + Voglibose 0.2 mg + Metformin 500 mg (SR)

  • Packaging: Blister | 10 x 15 Tablets

GLIMIDAC MV 2

  • Composition: Glimepiride 2 mg + Voglibose 0.2 mg + Metformin 500 mg (SR)

  • Packaging: Blister | 10 x 15 Tablets

GLIMIDAC MV 3.2

  • Composition: Glimepiride 3 mg + Voglibose 0.2 mg + Metformin 500 mg (SR)

  • Packaging: Blister | 10 x 15 Tablets

GLIMIDAC MV 1 FORTE

  • Composition: Glimepiride 1 mg + Voglibose 0.3 mg + Metformin 500 mg (SR)

  • Packaging: Blister | 10 x 15 Tablets

GLIMIDAC MV 2 FORTE

  • Composition: Glimepiride 2 mg + Voglibose 0.3 mg + Metformin 500 mg (SR)

  • Packaging: Blister | 10 x 15 Tablets

Key Benefits:

Triple Mechanism of Action:

  • Glimepiride: Stimulates insulin secretion from pancreatic β-cells.

  • Metformin: Reduces hepatic glucose output and improves peripheral insulin sensitivity.

  • Voglibose: Slows carbohydrate absorption in the intestines, reducing postprandial glucose spikes.

  • Effectively controls fasting and postprandial blood glucose levels.

  • Ideal for Indian dietary patterns rich in carbohydrates.

  • Improves HbA1c more significantly than dual therapy.

  • Helps delay the progression of diabetes and its complications.

  • Convenient once-daily dosing promotes better adherence.

Indications:

  • Type 2 Diabetes Mellitus with inadequate control on dual oral therapy.

  • Patients with prominent postprandial hyperglycemia.

  • Obese or insulin-resistant patients with elevated HbA1c.

  • Suitable before progressing to injectable insulin therapy.

Dosage & Administration:

  • Recommended dose: One tablet once daily, preferably with the first major meal of the day.

  • Dosage must be individualized based on patient response and physician’s judgment.

  • Regular monitoring of blood glucose, HbA1c, renal, and hepatic function is essential.

Precautions & Warnings:

  • Not suitable for Type 1 Diabetes or Diabetic Ketoacidosis.

  • Caution in patients with renal or hepatic impairment, GI disorders, or hypoglycemia risk.

  • Avoid use during pregnancy and lactation.

  • Stop use if persistent hypoglycemia, GI symptoms, or signs of lactic acidosis occur.

Possible Side Effects:

  • Hypoglycemia (especially with missed meals).

  • Flatulence, bloating, and diarrhea (due to Voglibose or Metformin).

  • Metallic taste, abdominal discomfort, or weight gain (Glimepiride-related).

  • Rare but serious: Lactic acidosis, liver enzyme elevation.

Conclusion:

The GLIMIDAC MV range provides an effective, triple-action oral therapy for managing T2DM with a focus on postprandial glucose control. Its once-daily regimen is well-suited for patients with carbohydrate-heavy diets and persistent hyperglycemia.

Choose GLIMIDAC MV for comprehensive, targeted, and patient-friendly glycemic management.

Note : Always Consult a physician before taking any medication, and do not rely solely on this information for medical advice.

For more such product information and similar product category Diabetic

You can also contact us  https://diabetes-cardiac.com/contact-us/

Related products